News

CGeneTech FGFR/VEGFR Dual Target Inhibitor Approved for Clinical Use in Advanced Solid Tumors

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-10-22
  • Views:0

(Summary description) Recently, CGeneTech announced that it has received the Notice of Drug Clinical Trial Approval from the State Drug Administration (NMPA) for the development of CGT-6321, a dual target inhibitor of FGFR/VEGFR, in advanced solid tumors, which is expected to be a potential first-in-class new drug in China.

CGeneTech FGFR/VEGFR Dual Target Inhibitor Approved for Clinical Use in Advanced Solid Tumors

(Summary description) Recently, CGeneTech announced that it has received the Notice of Drug Clinical Trial Approval from the State Drug Administration (NMPA) for the development of CGT-6321, a dual target inhibitor of FGFR/VEGFR, in advanced solid tumors, which is expected to be a potential first-in-class new drug in China.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-10-22
  • Views:0

  Recently, CGeneTech announced that it has received the Notice of Drug Clinical Trial Approval from the State Drug Administration (NMPA) for the development of CGT-6321, a dual target inhibitor of FGFR/VEGFR, in advanced solid tumors, which is expected to be a potential first-in-class new drug in China.

  Founded in 2010, CGeneTech is a biotechnology company dedicated to the development of small molecule drugs in the fields of hypoglycemia, antitumor and rare diseases. Since its establishment, the company has built a rich pipeline of Class 1 innovative drugs. Its self-developed Centigliptin phosphate, a novel DPP-4 inhibitor, is in Phase 3 clinical trials and all subjects are expected to complete Phase 3 clinical trials by mid-2022. Based on the results of subjects who completed the trial, Sengliptin phosphate demonstrated a favorable safety profile and glycated hemoglobin lowering effect. If the clinical efficacy endpoints are met, its approval will fill the gap in the domestic production of DPP-4 inhibitors (the approved ones are now registered as imports) and has broad market prospects.

  The clinical approval of CGT-6321 is another heavyweight product after Cetagliptin phosphate. It is an FGFR/VEGFR inhibitor for the treatment of advanced solid tumors. According to preclinical studies, CGT-6321 showed good safety, tolerability and pharmacokinetic characteristics in animals, and demonstrated high anti-tumor activity in several tumor cell lines and animal models. Based on the new molecular structure design, CGT-6321 has shown higher selectivity and better therapeutic efficacy in preclinical studies. It is effective not only in FGFR-positive patients, but also in FGFR-negative patients, which can significantly expand the clinical application. Compared with multi-kinase inhibitors, CGT-6321 is expected to achieve better therapeutic effects and provides ample room for subsequent single-agent and combination studies.

Brainstorming

Brainstorming | Exploring the Ocean of Stars through Metabolism

With the advancement of the Healthy China 2030 Plan, chronic disease drugs have become a focus of pharmaceutical research and development. Among them, the development of cardiovascular, lipid-lowering, and hypoglycemic and weight loss drugs has become a hot track in the industry. Recently, R&D clients and Haomai Technology held a "brainstorming session" in Zhuhai, focusing on clinical needs, industry trends, and the latest drug development trends in the field of metabolic diseases. Dr. Yu Qiang, founder and CEO of Shengshi Taike, attended the conference and explored the vast universe of chronic disease drugs with guests starting from metabolism.
2024-05-28
Shengshi

Shengshi Taike has once again been listed on the "Top 50 Most Influential Medical and Health Enterprises in China" list

Recently, CHC Medical Consulting and CITIC Securities officially released the "2023 China Healthcare Industry Investment and Financing Honor List". As an innovative pharmaceutical company in the commercialization stage, Shengshi Taike has once again been listed in this category and won the honor of being one of the top 50 most influential medical and health enterprises in China in 2023.
2024-05-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO